Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Axonics (AXNX) Stock Forecast & Price Target

Axonics logo
Get the Latest News and Ratings for AXNX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Axonics and its competitors.

Sign Up

AXNX Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
10 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$71.00$71.00$69.57$71.60
Forecasted Upside0.03% Upside0.03% Upside0.81% Upside14.45% Upside
Consensus Rating
Hold
Hold
Hold
Buy

AXNX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AXNX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Axonics Stock vs. The Competition

TypeAxonicsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.81
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside0.03% Upside25,828.59% Upside14.54% Upside
News Sentiment Rating
Neutral News

See Recent AXNX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/8/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingHold
2/29/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingSector Perform ➝ Sector Perform$71.00+4.34%
1/12/2024Truist Financial
2 of 5 stars
 Reiterated RatingBuy ➝ Hold$73.00 ➝ $71.00+3.50%
1/12/2024CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral
1/12/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Neutral$75.00 ➝ $71.00+3.32%
1/12/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$71.00+3.32%
1/10/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Equal Weight$68.00 ➝ $71.00+2.82%
1/9/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
10/31/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$76.00 ➝ $69.00+39.39%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
7/28/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$69.00 ➝ $70.00+32.08%
7/28/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$70.00 ➝ $71.00+33.96%
7/14/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$75.00+43.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:09 AM ET.


AXNX Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Axonics is $71.00, with a high forecast of $71.00 and a low forecast of $71.00.

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 8 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AXNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXNX, but not buy additional shares or sell existing shares.

According to analysts, Axonics's stock has a predicted upside of 0.03% based on their 12-month stock forecasts.

Axonics has been rated by research analysts at Needham & Company LLC in the past 90 days.

Analysts like Axonics less than other "medical" companies. The consensus rating for Axonics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AXNX compares to other companies.


This page (NASDAQ:AXNX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners